

## Special Issue

# Targeted Radiation Therapy and Molecular Imaging in Neuroendocrine Cancer

### Message from the Guest Editor

Neuroendocrine tumors (NETs) represent a group of highly heterogeneous neoplasms that can occur in different organs with an estimated incidence of less than 1/100,000 cases. They generally show an indolent growth rate. Recently, the interest in the use of radioligand therapy (RTL) in the treatment of neuroendocrine tumors has grown, emerging as a therapeutic area in the field of both nuclear medicine and oncology. Diagnostic tools have also improved. RTL has been demonstrated to be well tolerated and economically sustainable, allowing for personalized medicine in the theragnostic era. Although well consolidated studies have already recognized the efficacy of this therapy, there is room to amplify its potentialities in terms of timing and the variety of neoplasms treated.

---

### Guest Editor

Dr. Giovanni Storto

IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy

---

### Deadline for manuscript submissions

closed (29 November 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/173010](https://mdpi.com/si/173010)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)